 Leap Therapeutics, Inc. Nasdaq: LPTX today presented updated clinical data from its recently completed Phase 12 clinical trial of DKN-01 in patients with advanced or recurrent esophagogastric cancer EGC at the 2020 ASCO GI annual meeting. 